AACR 2021: Humanized IL17A/IL17F mouse model provides a preclinical tool for the evaluation of therapeutic drugs targeting to IL-17 pathway
Interleukin 17 (IL-17) is described as a pro-inflammatory cytokine produced by activated CD4 cells. Evidence shows that IL-17 is highly up-regulated at sites of inflammatory…
Read more
AACR 2021: Humanized CCR8 Mouse Model Provides A Translational Tool For Anti-Human CCR8 Antibody Drug Development
CCR8 is reported as an important chemokine receptor expressed on intra-tumoral Tregs and plays a critical role in CCR8+ Treg-mediated immunosuppression via inducing STAT3-dependent overexpression…
Read more
AACR 2021: Humanized IL6/hIL6R mouse model supports the evaluation of therapeutic drug candidates targeting human IL6 and IL6 receptor
Interleukin 6 (IL-6) gene encodes a cytokine that functions in inflammation and the maturation of B cells and is a potent pleiotropic cytokine that regulates…
Read more
AACR 2021: Anti-GCGR in vivo efficacy evaluated in a new humanized hGCGR mouse model
GCGR (glucagon receptor) is a G-protein-coupled seven-transmembrane protein, a typical representative of the class B GPCR family. Animals homozygous for a targeted mutation in this…
Read more
AACR 2021: Humanized B-hC5AR1 mouse model for evaluation of anti-C5AR1 mAb in vivo efficacy
C5AR1 (complement C5a receptor 1) is a classical G protein-coupled receptor that is mainly expressed on granulocytes, monocytes, dendritic cells and MDSCs (Myeloid-derived suppressor cells)…
Read more
AACR 2021: Novel Engineered B-NDG B2M KO Mice Plus Shows Delayed GvHD response and Favorable GvL Immune Profiling After hPBMC Engraftment
Severely immunodeficient mouse strains, such as NOD.Cg-Prkdcscid Il2rg-/-, have been used to study the immune response in humans. These mice lack T, B and natural…
Read more
AACR 2021: Improved LAG-3 humanized knock-in mouse model for assessment of mono- and combination therapy strategies for cancer treatment
In recent years, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. One of the potential therapeutic targets that seems increasingly attractive is LAG-3 (Lymphocyte activation…
Read more
AACR 2021: Double-humanized 4-1BB/4-1BBL mouse is an advanced model for liver toxicity and efficacy evaluation of 4-1BB therapeutic antibodies
4-1BB is an activation-induced costimulatory TNF receptor family member which is expressed on a variety of cell types such as activated T cells, NK cells,…
Read more
AACR 2021: Human CD73 knock-in mice facilitate evaluation of in vivo efficacy of anti-human CD73 cancer immunotherapies
In recent years, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, most patients with solid cancers do not respond to the current ICIs against…
Read more
AACR 2021: Evaluating anti-SIRPα in vivo efficacy in humanized B-NDG hSIRPA mice and B-NDG hSIRPA/hCD47 mice
The CD47/ Signal regulatory protein α (SIRPα) axis regulates myeloid cell activation and functions as a crucial myeloid-specific immune checkpoint. CD47 is highly expressed on…
Read more
AACR 2021: TNFR2 and PD-1/PD-L1/TNFR2 humanized mice aid exploration of combination strategies to overcome tumor immune escape mechanisms
Tumor necrosis factor receptor 2 (TNFR2), also known as tumor necrosis factor receptor superfamily member 1B (TNFRSF1B), is a transmembrane protein, which can mediate both…
Read more
AACR 2021: Novel human B7-H3 knock-in mice demonstrate efficacy of anti-B7-H3 immunotherapy in vivo
In recent years, immune checkpoint inhibitors (ICIs), particularly against PD-1/PD-L1, have revolutionized cancer treatment. However, ICI monotherapy only benefits a portion of cancer patients, while…
Read more